Litigation Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
✉ Email this page to a colleague
Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-04-30 |
| Court | District Court, D. Delaware | Date Terminated | 2022-12-14 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Parties | APOTEX CORP. | ||
| Patents | 10,071,977; 10,149,829; 10,376,487; 10,449,176; 10,517,860; 7,476,652; 7,713,930; 8,344,011; 8,679,069; 8,785,492; 8,992,486; 9,060,995; 9,181,162; 9,526,844; 9,539,234; 9,549,913; 9,604,008; 9,730,910; 9,855,241; RE46,604 | ||
| Attorneys | Eric J. Choi | ||
| Firms | Shaw Keller LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.
Biologic Drugs cited in Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .
Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-04-30 | 1 | Complaint | of Vanda’s U.S. Patent Nos. RE46,604 (“the RE604 patent”); 9,060,995 (“the ’995 patent”); 9,539,234 (… V. THE PATENTS-IN-SUIT (U.S. PATENT NOS. RE46,604; 9,060,995; 9,539,234; 9,549,913;… U.S. Patent No. 9,060,995 29. Vanda is the owner… (“the ’234 patent”); 9,549,913 (“the ’913 patent”); 9,730,910 (“the ’910 patent”); and Case 1:18-cv-00651…#: 2 9,855,241 (“the ’241 patent”) (collectively “the Asserted Patents”), which, in relevant part, | External link to document |
| 2019-12-03 | 113 | Notice of Service | U.S. Patent No. 10,071,977; (2) Defendants' Amended Invalidity Contentions Regarding U.S. Patent No. 10,149,829… 30 April 2018 1:18-cv-00651 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-12-10 | 114 | Notice of Service | Supplemental Infringement Contentions for U.S. Patent No. 10,071,977 to Teva; and (2) Vanda's Supplemental Infringement…Infringement Contentions for U.S. Patent No. 10,071,977 to MSN filed by Vanda Pharmaceuticals Inc..(Fahnestock… 30 April 2018 1:18-cv-00651 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-12-23 | 117 | Notice of Service | Invalidity Contentions Concerning U.S. Patent No. 10,071,977 2) Defendants Second Amended Invalidity …Invalidity Contentions Regarding U.S. Patent No. 10,149,829 3) Defendants Third Amended Invalidity Contentions … 30 April 2018 1:18-cv-00651 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
